Skip to main content

Table 1 Baseline Clinical Characteristics of Study Patients

From: Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study

 

All Patients

Trimetazidine

Placebo

Mean age (years)

65.4 ± 6.3

65.6 ± 5.7

65.2 ± 7

Male

24

11

13

Female

8

5

3

BMI

25.4 ± 3.2

25.7 ± 3.3

25.2 ± 3.3

Baseline glucose

164.6 ± 26.2

166.9 ± 21.9

162.2 ± 30.4

Triglycerides at baseline

238.1 ± 59.5

231.3 ± 43.7

244.9 ± 72.9

Triglycerides at randomisation

185.7 ± 46.4

180.5 ± 34

191 ± 57

Cholesterol at baseline

264.5 ± 27.8

263.3 ± 29.3

265.2 ± 27.2

Cholesterol at randomisation

198.3 ± 20.8

197.8 ± 21.9

198.8 ± 20.4

HBA1c

7.6 ± 0.8

7.7 ± 1

7.5 ± 0.6

Prior MI

18

9

9

Prior CABG

7

4

3

Prior PTCA

12

6

8

Carotid Atherosclerosis

12

7

5

Coronary atherosclerosis

   

   1 vessel disease

1

0

1

   2 vessel disease

14

6

8

   3 vessel disease

16

9

7

   any vessel + graft

1

1

0

   distal disease

23

12

11

USE OF DRUGS AT RANDOMISATION

   

Aspirin/ticlopidine

18

12

14

Clopidogrel

6

6

4

Anticoagulants

6

5

6

Digitalis

28

13

15

Diuretics

31

16

15

Nitrates

18

8

10

B-blockers

23

11

12

Ca-antagonists

14

9

6

ACE-I

29

14

15

ARB

4

2

2

Statins

30

14

16

Oral hypoglycaemics

25

12

13

Insulin

7

4

3

  1. Clinical features of study patients. Clinical characteristics, incidence of previous myocardial infarction or revascularization procedures in patients randomized to trimetazidine or placebo. No significant differences were detected between groups. BMI = body mass index, MI = myocardial infarction, CABG = coronary artery by-pass grafting, PC I = percutaneous coronary interventions.